INS and diabetes mellitus: Oral diabetes agents, such as insulin secretagogues, metformin, and thiazolidinediones are generally not recommended in CFRD [123], though some early research suggests the insulin secretagogue repaglinide may have some utility in the treatment of early CFRD [124].